EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis

Abdullah Alshehri, Yashpal S Chhonker, Veenu Bala, Constant Edi, Catherine M Bjerum, Benjamin G Koudou, Lucy N John, Oriol Mitjà, Michael Marks, Christopher L King, Daryl J Murry iD

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Abdullah Alshehri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Neb…. Hauptthemen laut MEDLINE: Elephantiasis, Filarial, Filaricides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals. Methodology / Principal findings In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti –infected ( n = 32) and uninfected ( n = 24) adults living in Côte d’Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM’s pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/ F , 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex. Conclusion/Significance We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF.

Trial registration

NCT02845713 ; NCT03664063

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elephantiasis, FilarialFilaricidesAnimalsFemaleIvermectinMass Drug AdministrationWuchereria bancroftiAlbendazole

Substanzen

IvermectinFilaricidesAlbendazole

Autor:innen und Institutionen

  • Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
  • Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Centre Suisse de Recherche Scientifique en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
  • Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
  • Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.

ORCID-Profile: Daryl J Murry

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Alshehri, A., Chhonker, Y. S., Bala, V., Edi, C., Bjerum, C. M., Koudou, B. G., John, L. N., Mitjà, O., Marks, M., King, C. L., & Murry, D. J. (2023). Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011319

Vancouver

Alshehri A, Chhonker YS, Bala V, Edi C, Bjerum CM, Koudou BG, et al. Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011319

BibTeX
@article{Alshehri2023,
  author = {Alshehri, Abdullah and Chhonker, Yashpal S and Bala, Veenu and Edi, Constant and Bjerum, Catherine M and Koudou, Benjamin G and John, Lucy N and Mitjà, Oriol and Marks, Michael and King, Christopher L and Murry, Daryl J},
  title = {Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011319}
}
Kostenlos starten →